ArticleActa pharmaceutica Sinica. B2018
Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma.
Article in Acta pharmaceutica Sinica. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.
- Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen.International journal of molecular sciences · 2021Pooled it
- Nanotechnology in Pediatric Neurology: Applications and Innovations.Pharmaceutics · 2026Review
- Co-delivery of endoplasmic reticulum-targeted photosensitizer and Ido-1 inhibitor potentiates immunotherapeutic efficacy in triple-negative breast cancer.Materials today. Bio · 2026Article
- Acriflavine-empowered IR780-PTX albumin nanoparticles for reinforced synergistic photochemotherapy.Advanced biotechnology · 2026Article
- Discovery of novel quinazoline derivatives containing trifluoromethyl against cell proliferation by targeting werner helicase.Molecular diversity · 2026Article
- Biomimetic Nanoparticles for Targeted and Efficient Cancer Therapy: Progress, Challenges and Perspectives.International journal of nanomedicine · 2026Review
- Physicochemical Stability and Cross-Context Validation of PEGylated Human Serum Albumin Nanoparticles for Dual Neurotrophin Delivery in the Rabbit Eye and Oxidative Stress Models.International journal of nanomedicine · 2026Article
- Functionalized albumin nanoparticles: A multifunctional platform for enhanced brain drug delivery.Materials today. Bio · 2025Review
- Opportunities in the translational pipeline for pediatric brain cancer therapies.Pediatric research · 2025Review
- Medulloblastoma: Molecular Targets and Innovative Theranostic Approaches.Pharmaceutics · 2025Review
- The neuroscience of cancer: Focus on neuropeptidergic systems.Acta pharmaceutica Sinica. B · 2025Review
- PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation.Pharmaceutics · 2025Review
- Nano particle loaded EZH2 inhibitors: Increased efficiency and reduced toxicity for malignant solid tumors.Journal of translational internal medicine · 2025Article
- Periodate-Mediated Cross-Linking for the Preparation of Catechol Conjugated Albumin Nanoparticles Used for in Vitro Drug Delivery.ACS applied bio materials · 2025Article
- Albumin and Polysorbate-80 Coated Sterile Nanosuspensions of Mebendazole for Glioblastoma Therapy.AAPS PharmSciTech · 2024Article
- The Neoteric Paradigm of Biomolecule-Functionalized Albumin-Based Targeted Cancer Therapeutics.AAPS PharmSciTech · 2024Review
- Preclinical Development of a Genetically Engineered Albumin-Binding Nanoparticle of Paclitaxel.Small science · 2024Article
- Article
- Red blood cell-derived materials for cancer therapy: Construction, distribution, and applications.Materials today. Bio · 2024Review
- GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The blood-brain barrier (BBB) and the poor ability of many drugs to cross that barrier greatly limits the efficacy of chemotherapies for glioblastoma multiforme (GBM). The present study exploits albumin as drug delivery vehicle to promote the chemotherapeutic efficacy of paclitaxel (PTX) by improving the stability and targeting efficiency of PTX/albumin nanoparticles (NPs). Here we characterize PTX-loaded human serum albumin (HSA) NPs stabilized with intramolecular disulfide bonds and modified with substance P (SP) peptide as the targeting ligand. The fabricated SP-HSA-PTX NPs exhibited satisfactory drug-loading content (7.89%) and entrapment efficiency (85.7%) with a spherical structure (about 150 nm) and zeta potential of -12.0 mV. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.